Skip to Content
Merck
All Photos(2)

Documents

C1335

Sigma-Aldrich

S-(−)-Carbidopa

≥98% (TLC), powder

Synonym(s):

(S)-3-(3,4-Dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid, S-(−)-α-Hydrazino-3,4-dihydroxy-2-methylbenzenepropanoic acid

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

Empirical Formula (Hill Notation):
C10H14N2O4
CAS Number:
28860-95-9
Molecular Weight:
226.23
EC Number:
249-271-9
MDL number:
MFCD00069231
UNSPSC Code:
12352202
PubChem Substance ID:
24892402
NACRES:
NA.77

Quality Level

200

Assay

≥98% (TLC)

form

powder

solubility

methanol and 1 drop HCl: 4.90-5.10 mg/mL, clear, colorless to faintly yellow

storage temp.

−20°C

SMILES string

CC(Cc1ccc(O)c(O)c1)(NN)C(O)=O

InChI

1S/C10H14N2O4/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6/h2-4,12-14H,5,11H2,1H3,(H,15,16)/t10-/m0/s1

InChI key

TZFNLOMSOLWIDK-JTQLQIEISA-N

Gene Information

human ... DDC(1644)

Looking for similar products? Visit Product Comparison Guide

General description

Carbidopa is used for treating restless legs (RL) syndrome and periodic leg movements in sleep (PLMS). Carbidopa along with levodopa is used to treat Parkinson′s disease.

Biochem/physiol Actions

Peripheral inhibitor of L-aromatic amino acid decarboxylase. When co-administered with L-DOPA, it prevents extra-CNS conversion to dopamine, thereby increasing CNS concentrations of effective compounds. Selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells by increasing H2O2 in these cell lines, which are sensitive to reactive oxygen species.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

S Kaakkola et al.
Journal of neurochemistry, 60(1), 137-144 (1993-01-01)
The effects of two new catechol-O-methyltransferase (COMT) inhibitors, OR-611 and Ro 40-7592, in combination with L-3,4-dihydroxyphenylalanine (L-dopa) with or without carbidopa on extracellular levels of dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), 3-O-methyldopa (3-OMD), and 5-hydroxyindoleacetic acid in rat
Levodopa with benserazide or carbidopa in Parkinson disease
Rinne UK and Molsa P
Neurology, 29(12), 1584-1589 (1979)
D Deleu et al.
Naunyn-Schmiedeberg's archives of pharmacology, 348(6), 576-581 (1993-12-01)
The effect of carbidopa on the pharmacokinetics and metabolism of levodopa (L-dopa) in blood plasma and skeletal muscle extracellular fluid (ECF) has been studied by repeated measurements in one beagle dog. The administration of a single dose of L-dopa (25
Hubert H Fernandez et al.
Parkinsonism & related disorders, 19(3), 339-345 (2013-01-05)
Levodopa-carbidopa intestinal gel (LCIG) delivered continuously via percutaneous endoscopic gastrojejunostomy (PEG-J) tube has been reported, mainly in small open-label studies, to significantly alleviate motor complications in Parkinson's disease (PD). A prospective open-label, 54-week, international study of LCIG is ongoing in
V K Datieva et al.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 112(10 Pt 2), 13-19 (2012-12-20)
The objective of this multicenter observational study "Optimization levodopa therapy for patients with Parkinson's disease" (OPTIMA) was to evaluate the current practice of prescribing levodopa to patients with Parkinson's disease (PD) by general practitioners and specialists in the treatment of
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service